4SC AGのRPE
4SC AGのRPEは何ですか。
4SC AGのRPEは53.619k€です。
RPEの定義は何ですか。
従業員1人当たりの収益（RPE）は、収益を組織の従業員の数で割ったものです。
XETRAのセクタHealth CareにおけるRPEの企業と比べる4SC AG
4SC AGは何をしますか。
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
4SC AGと類似のrpe
- Jumia Technologies AGのRPEは53.468k$です。
- LSL Property Services PlcのRPEは53.511k£です。
- NeovascのRPEは53.549k$です。
- Stanley FurnitureのRPEは53.560k$です。
- VR Education PlcのRPEは53.618k€です。
- City of London plcのRPEは53.618k£です。
- 4SC AGのRPEは53.619k€です。
- Greenpro CapitalのRPEは53.672k$です。
- Xinyang MaojianのRPEは53.752kHKD$です。
- I.Céram SAのRPEは53.842k€です。
- Génomic Vision SAのRPEは53.852k€です。
- Profound MedicalのRPEは53.973k$です。
- NikolaのRPEは54.018k$です。